Antimicrobial resistance

Consideration as an adverse drug event

Steven J. Martin, Scott T. Micek, G Christopher Wood

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Antimicrobial resistance has increased dramatically in the past 15 to 20 yrs and presents a patient safety concern unlike any other in the intensive care unit. Antimicrobial resistance in critically ill patients increases morbidity, mortality, length of hospital stay, and healthcare costs. Some organisms may have intrinsically high levels of resistance or may be spread between patients by poor infection control practices. However, a major driver of antimicrobial resistance is antibiotic use. As such, the development of antimicrobial resistance can often be thought of as an adverse drug event. This article explores the link between drug use, drug dosing, other selective pressures and resistance, and describes concepts to minimize the negative impact of antimicrobial therapy. Two broad themes of these concepts are minimizing the use of antibiotics whenever possible and optimizing antibiotic usage when they are needed. Strategies for minimizing the use of antimicrobials include using optimal diagnostic procedures to ensure the need for antimicrobials, streamlining or discontinuing therapy when possible based on culture results, and using the shortest duration of therapy needed for documented infections. Strategies for optimizing antimicrobial use include using optimal dosing based on the manufacturer's instructions and current pharmacodynamic data, guiding better prescribing based on local susceptibility patterns and formulary restriction, and avoiding drugs with more propensity to foster resistance.

Original languageEnglish (US)
JournalCritical care medicine
Volume38
Issue number6 SUPPL.
DOIs
StatePublished - Jan 1 2010

Fingerprint

Drug-Related Side Effects and Adverse Reactions
Length of Stay
Pharmaceutical Preparations
Anti-Bacterial Agents
Formularies
Hospital Costs
Patient Safety
Infection Control
Microbial Drug Resistance
Critical Illness
Health Care Costs
Intensive Care Units
Therapeutics
Morbidity
Mortality
Infection

All Science Journal Classification (ASJC) codes

  • Critical Care and Intensive Care Medicine

Cite this

Antimicrobial resistance : Consideration as an adverse drug event. / Martin, Steven J.; Micek, Scott T.; Wood, G Christopher.

In: Critical care medicine, Vol. 38, No. 6 SUPPL., 01.01.2010.

Research output: Contribution to journalArticle

Martin, Steven J. ; Micek, Scott T. ; Wood, G Christopher. / Antimicrobial resistance : Consideration as an adverse drug event. In: Critical care medicine. 2010 ; Vol. 38, No. 6 SUPPL.
@article{3e06bf021ab7417b9652ab01dc989b0e,
title = "Antimicrobial resistance: Consideration as an adverse drug event",
abstract = "Antimicrobial resistance has increased dramatically in the past 15 to 20 yrs and presents a patient safety concern unlike any other in the intensive care unit. Antimicrobial resistance in critically ill patients increases morbidity, mortality, length of hospital stay, and healthcare costs. Some organisms may have intrinsically high levels of resistance or may be spread between patients by poor infection control practices. However, a major driver of antimicrobial resistance is antibiotic use. As such, the development of antimicrobial resistance can often be thought of as an adverse drug event. This article explores the link between drug use, drug dosing, other selective pressures and resistance, and describes concepts to minimize the negative impact of antimicrobial therapy. Two broad themes of these concepts are minimizing the use of antibiotics whenever possible and optimizing antibiotic usage when they are needed. Strategies for minimizing the use of antimicrobials include using optimal diagnostic procedures to ensure the need for antimicrobials, streamlining or discontinuing therapy when possible based on culture results, and using the shortest duration of therapy needed for documented infections. Strategies for optimizing antimicrobial use include using optimal dosing based on the manufacturer's instructions and current pharmacodynamic data, guiding better prescribing based on local susceptibility patterns and formulary restriction, and avoiding drugs with more propensity to foster resistance.",
author = "Martin, {Steven J.} and Micek, {Scott T.} and Wood, {G Christopher}",
year = "2010",
month = "1",
day = "1",
doi = "10.1097/CCM.0b013e3181de0c26",
language = "English (US)",
volume = "38",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "6 SUPPL.",

}

TY - JOUR

T1 - Antimicrobial resistance

T2 - Consideration as an adverse drug event

AU - Martin, Steven J.

AU - Micek, Scott T.

AU - Wood, G Christopher

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Antimicrobial resistance has increased dramatically in the past 15 to 20 yrs and presents a patient safety concern unlike any other in the intensive care unit. Antimicrobial resistance in critically ill patients increases morbidity, mortality, length of hospital stay, and healthcare costs. Some organisms may have intrinsically high levels of resistance or may be spread between patients by poor infection control practices. However, a major driver of antimicrobial resistance is antibiotic use. As such, the development of antimicrobial resistance can often be thought of as an adverse drug event. This article explores the link between drug use, drug dosing, other selective pressures and resistance, and describes concepts to minimize the negative impact of antimicrobial therapy. Two broad themes of these concepts are minimizing the use of antibiotics whenever possible and optimizing antibiotic usage when they are needed. Strategies for minimizing the use of antimicrobials include using optimal diagnostic procedures to ensure the need for antimicrobials, streamlining or discontinuing therapy when possible based on culture results, and using the shortest duration of therapy needed for documented infections. Strategies for optimizing antimicrobial use include using optimal dosing based on the manufacturer's instructions and current pharmacodynamic data, guiding better prescribing based on local susceptibility patterns and formulary restriction, and avoiding drugs with more propensity to foster resistance.

AB - Antimicrobial resistance has increased dramatically in the past 15 to 20 yrs and presents a patient safety concern unlike any other in the intensive care unit. Antimicrobial resistance in critically ill patients increases morbidity, mortality, length of hospital stay, and healthcare costs. Some organisms may have intrinsically high levels of resistance or may be spread between patients by poor infection control practices. However, a major driver of antimicrobial resistance is antibiotic use. As such, the development of antimicrobial resistance can often be thought of as an adverse drug event. This article explores the link between drug use, drug dosing, other selective pressures and resistance, and describes concepts to minimize the negative impact of antimicrobial therapy. Two broad themes of these concepts are minimizing the use of antibiotics whenever possible and optimizing antibiotic usage when they are needed. Strategies for minimizing the use of antimicrobials include using optimal diagnostic procedures to ensure the need for antimicrobials, streamlining or discontinuing therapy when possible based on culture results, and using the shortest duration of therapy needed for documented infections. Strategies for optimizing antimicrobial use include using optimal dosing based on the manufacturer's instructions and current pharmacodynamic data, guiding better prescribing based on local susceptibility patterns and formulary restriction, and avoiding drugs with more propensity to foster resistance.

UR - http://www.scopus.com/inward/record.url?scp=77953073448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953073448&partnerID=8YFLogxK

U2 - 10.1097/CCM.0b013e3181de0c26

DO - 10.1097/CCM.0b013e3181de0c26

M3 - Article

VL - 38

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 6 SUPPL.

ER -